97-26113. Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 62, Number 191 (Thursday, October 2, 1997)]
    [Notices]
    [Page 51669]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-26113]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). At least one 
    portion of the meeting will be closed to the public.
        Name of Committee: Circulatory System Devices Panel of the Medical 
    Devices Advisory Committee.
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA regulatory issues.
        Date and Time: The meeting will be held on October 24, 1997, 9:30 
    a.m. to 6 p.m.
        Location: Gaithersburg Marriott Washingtonian Center, Salons C and 
    D, 9751 Washingtonian Blvd., Gaithersburg, MD.
        Contact Person: John E. Stuhlmuller, Center for Devices and 
    Radiological Health (HFZ-450), Food and Drug Administration, 9200 
    Corporate Blvd., Rockville, MD 20850, 301-443-8243, ext. 157, or FDA 
    Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
    the Washington, DC area), code 12625. Please call the Information Line 
    for up-to-date information on this meeting.
        Agenda: The committee is being asked to provide input to the agency 
    regarding the design of clinical trials to support premarket approval 
    applications for devices intended to treat atrial septal defects, 
    patent foramen ovale, and patent ductus arteriosus. Of particular 
    concern are the following issues: What are the appropriate controls to 
    be used in such trials? What are the appropriate safety and efficacy 
    measures? When should assessments of these measures be made?
        Procedure: On October 24, 1997, from 12:30 p.m. to 6 p.m., the 
    meeting is open to the public. Interested persons may present data, 
    information, or views, orally or in writing, on issues pending before 
    the committee. Written submissions may be made to the contact person by 
    October 14, 1997. Oral presentations from the public will be scheduled 
    between approximately 12:30 p.m. and 1:30 p.m. Time allotted for each 
    presentation may be limited. Those desiring to make formal oral 
    presentations should notify the contact person before October 14, 1997, 
    and submit a brief statement of the general nature of the evidence or 
    arguments they wish to present, the names and addresses of proposed 
    participants, and an indication of the approximate time requested to 
    make their presentation.
        Closed Committee Deliberations: On October 24, 1997, from 9:30 a.m. 
    to 12:30 p.m., the meeting will be closed to permit discussion and 
    review of trade secret and/or confidential information (5 U.S.C. 
    552b(c)(4)). FDA staff will present trade secret and/or confidential 
    information regarding pending and future circulatory system device 
    submissions.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: September 25, 1997.
    Michael A. Friedman,
    Deputy Commissioner for Operations.
    [FR Doc. 97-26113 Filed 10-1-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
10/02/1997
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
97-26113
Pages:
51669-51669 (1 pages)
PDF File:
97-26113.pdf